
Ole Steen Nielsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8528564/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet, The, 2001, 358, 1421-1423.	6.3	1,249
2	Bone metastases: pathophysiology and management policy Journal of Clinical Oncology, 1991, 9, 509-524.	0.8	446
3	Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiotherapy and Oncology, 1998, 47, 233-240.	0.3	284
4	Hypoxia in human soft tissue sarcomas: Adverse impact on survival and no association with p53 mutations. British Journal of Cancer, 2001, 84, 1070-1075.	2.9	204
5	Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group Journal of Clinical Oncology, 1996, 14, 1146-1155.	0.8	170
6	Extraskeletal Osteosarcomas. American Journal of Surgical Pathology, 1998, 22, 588-594.	2.1	168
7	Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group Journal of Clinical Oncology, 1997, 15, 3030-3037.	0.8	157
8	The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. International Journal of Radiation Oncology Biology Physics, 1996, 35, 701-708.	0.4	138
9	Intradermal and subcutaneous leiomyosarcoma: a clinicopathological and immunohistochemical study of 41 cases. Journal of Cutaneous Pathology, 1996, 23, 458-463.	0.7	122
10	Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiotherapy and Oncology, 2003, 67, 339-344.	0.3	114
11	High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. British Journal of Cancer, 1998, 78, 1634-1639.	2.9	102
12	Treatment of aggressive fibromatosis: A retrospective study of 72 patients followed for 1-27 years. Acta Orthopaedica, 2002, 73, 213-219.	1.4	100
13	Elevated Serum Insulin-Like Growth Factor-Binding Protein 2 (IGFBP-2) and Decreased IGFBP-3 in Epithelial Ovarian Cancer: Correlation with Cancer Antigen 125 and Tumor-Associated Trypsin Inhibitor. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2308-2313.	1.8	74
14	Palliative irradiation of bone metastases. Cancer Treatment Reviews, 1989, 16, 41-48.	3.4	72
15	Neoadjuvant Chemotherapy with Cisplatin and Methotrexate in Patients with Muscle-Invasive Bladder Tumours. Acta Oncológica, 2002, 41, 447-456.	0.8	71
16	Surveillance alone versus radiotherapy after orchiectomy for clinical stage I nonseminomatous testicular cancer. Danish Testicular Cancer Study Group Journal of Clinical Oncology, 1991, 9, 1543-1548.	0.8	66
17	A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. British Journal of Cancer, 1982, 46, 904-911.	2.9	61
18	A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement. Cancer Chemotherapy and Pharmacology, 1991, 28, 465-469.	1.1	55

OLE STEEN NIELSEN

#	Article	IF	CITATIONS
19	Urinary symptoms, potency, and quality of life in patients with localized prostate cancer followed up with deferred treatment. Urology, 1998, 52, 1055-1062.	0.5	50
20	Importance of preheating temperature and time for the induction of thermotolerance in a solid tumour in vivo. British Journal of Cancer, 1982, 46, 894-903.	2.9	49
21	Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event) Tj ETQq1 1 0.78	431 d.c gBT	/Ouerlock 1(
22	Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 1991, 28, 63-68.	1.1	36
23	Influence of thermotolerance on the interaction between hyperthermia and radiation in a solid tumour <i>in vivo</i> . British Journal of Radiology, 1983, 56, 267-273.	1.0	35
24	Soft-tissue sarcoma of the thigh: Surgical margin influences local recurrence but not survival in 152 patients. Acta Orthopaedica, 2001, 72, 72-77.	1.4	33
25	High frequency of <i>MYC</i> gene amplification is a common feature of radiationâ€induced sarcomas. Further results from EORTC STBSG TL 01/01. Genes Chromosomes and Cancer, 2013, 52, 93-98.	1.5	30
26	Is placental alkaline phosphatase (PLAP) a useful marker for seminoma?. European Journal of Cancer & Clinical Oncology, 1990, 26, 1049-1054.	0.9	29
27	Retroperitoneal soft tissue sarcomas: a treatment challenge and a call for randomized trials. Radiotherapy and Oncology, 2002, 65, 133-136.	0.3	29
28	Tumour Oxygenation Assessed by Polarographic Needle Electrodes and Bioenergetic Status Measured by ³¹ P Magnetic Resonance Spectroscopy in Human Soft Tissue Tumours. Acta Oncológica, 1997, 36, 565-571.	0.8	25
29	Fractionated radiotherapy for metastatic bone pain: evidence-based medicine or?. International Journal of Radiation Oncology Biology Physics, 2000, 46, 681-682.	0.4	21
30	Selective assessment of in vitro radiosensitivity of tumour cells and fibroblasts from single tumour biopsies using immunocytochemical identification of colonies in the soft agar clonogenic assay. Radiotherapy and Oncology, 1995, 37, 87-99.	0.3	20
31	Orgotein in Radiation Treatment of Bladder Cancer: A report on allergic reactions and lack of radioprotective effect. Acta Oncológica, 1987, 26, 101-104.	0.8	19
32	Platinum analogue combination chemotherapy: Cisplatin, carboplatin, and methotrexate in patients with metastatic urothelial tract tumors. A phase II trial with evaluation of prognostic factors. Cancer, 1995, 76, 1797-1803.	2.0	18
33	In vitro radiosensitivity of tumour cells and fibroblasts derived from head and neck carcinomas: mutual relationship and correlation with clinical data. British Journal of Cancer, 1999, 79, 1074-1084.	2.9	16
34	EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma. Sarcoma, 1997, 1, 99-101.	0.7	15
35	The Importance of Reference Gene Analysis of Formalin-Fixed, Paraffin-Embedded Samples from Sarcoma Patients — An Often Underestimated Problem. Translational Oncology, 2014, 7, 687-693.	1.7	15
36	An assessment of combined tumour markers in patients with seminoma: placental alkaline phosphatase (PLAP), lactate dehydrogenase (LD) and β human chorionic gonadotrophin (β HCG). British Journal of Cancer, 1991, 64, 537-542.	2.9	14

OLE STEEN NIELSEN

#	Article	IF	CITATIONS
37	Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: Results from the scandinavian prostate cancer group study 5. Scandinavian Journal of Urology and Nephrology, 2005, 39, 42-48.	1.4	14
38	The importance of standardized treatment in high-grade osteosarcoma: 30 years of experience from a hospital-based database. Acta Oncológica, 2015, 54, 17-24.	0.8	14
39	Renal damage after total body irradiation in a mouse model for bone marrow transplantation: effect of radiation dose rate. Radiotherapy and Oncology, 1995, 34, 203-209.	0.3	13
40	The effect of sequence and time interval between cyclophosphamide and total body irradiation on lung and bone marrow damage following bone marrow transplantation in mice. Radiotherapy and Oncology, 1993, 29, 51-59.	0.3	10
41	A prognostic profile of hypoxia-induced genes for localised high-grade soft tissue sarcoma. British Journal of Cancer, 2016, 115, 1096-1104.	2.9	10
42	Assessment of palliative response in hyperthermia. International Journal of Hyperthermia, 1992, 8, 1-10.	1.1	8
43	Effect of combined 5-fluorouracil and radiation on murine hematopoietic tissue. Radiotherapy and Oncology, 1988, 13, 145-152.	0.3	7
44	Chemotherapy-induced changes of CA 125 in patients with epithelial ovarian cancer. Gynecologic Oncology, 2005, 97, 410-412.	0.6	7
45	Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group. Anti-Cancer Drugs, 2000, 11, 433-437.	0.7	5
46	Lack of Radiation Protective Effect of Orgotein in Normal and Malignant Mammalian Cells. Acta Radiologica: Oncology, Radiation, Physics, Biology, 1979, 18, 305-312.	0.3	4
47	Repair capacity of mouse lung after total body irradiation alone or combined with cyclophosphamide. Radiotherapy and Oncology, 1996, 40, 249-257.	0.3	4
48	A comparison between the effect of step-down heating in a tumour and a normal tissue invivo. International Journal of Hyperthermia, 1991, 7, 519-526.	1.1	3
49	Systemic Mitomycin C As Second-Line Treatment For Metastatic Urothelial Cancer. Acta Oncológica, 1995, 34, 978-979.	0.8	2
50	Effects of step-down and step-up heating on the development of thermotolerance in a C3H mammary carcinoma <i>in vivo</i> . International Journal of Hyperthermia, 1995, 11, 231-239.	1.1	1
51	Role of systemic treatment in adult soft tissue sarcomas. European Journal of Cancer, Supplement, 2003, 1, 249-259.	2.2	1
52	Status of hyperthermic oncology in Europe: Results of an ESHO survey. International Journal of Hyperthermia, 1995, 11, 323-327.	1.1	0
53	23 Assessment of molecular determinants of development and treatment efficacy in radiation induced sarcoma (RIS) — eortc translational research project 01/01. Radiotherapy and Oncology, 2006, 78, S8-S9.	0.3	0